
zzso zzso zzso zzso has broad zzso zzso activity and zzso a variety of zzso zzso involved in the folate zzso This study was designed to zzso determine the zzso dose zzso zzso zzso zzso and zzso of zzso combined with zzso zzso determine a recommended dose for phase II zzso and zzso collect anecdotal information on the zzso activity of zzso combined with zzso 

Patients with solid tumors received zzso zzso over 10 minutes and zzso over 2 hours once every 21 zzso In cohort 1, both agents were administered on day 1 starting with zzso 300 zzso and zzso 60 zzso In cohort 2, zzso zzso or 600 zzso was administered on day 1, followed by zzso (75 zzso on day zzso 

In cohort 1, 40 zzso patients received 159 courses of zzso The zzso was zzso 600 zzso 100 zzso zzso were zzso zzso and delayed zzso zzso before zzso therapy did not influence zzso zzso Eleven objective zzso included one complete response in a patient with relapsed zzso cell head and neck zzso and partial responses in four of ten patients with zzso zzso zzso In cohort 2, 11 zzso patients received 23 courses of zzso The zzso was zzso 600 zzso and zzso 75 zzso zzso were zzso zzso zzso and skin zzso Two patients died of zzso complications during the zzso Two patients had objective zzso (one zzso patient, one colon cancer zzso 

The combination of zzso and zzso is clinically active, and administering both agents on day 1 is superior to a split zzso Further development of this combination for zzso is zzso 

